Is there a place for cyclophosphamide in the treatment of giant-cell arteritis? A case series and systematic review

Abstract Objective To report on the effectiveness of cyclophosphamide (CYC) to treat glucocorticoid (GC)-dependent giant-cell arteritis (GCA) and/or severe GC-related side effects. Methods Fifteen patients with GCA and treated with CYC were retrieved from the computerized patient-record system. Gluc...

Full description

Saved in:
Bibliographic Details
Published in:Seminars in arthritis and rheumatism 2013-08, Vol.43 (1), p.105-112
Main Authors: de Boysson, Hubert, MD, Boutemy, Jonathan, MD, Creveuil, Christian, MD, Ollivier, Yann, MD, Letellier, Philippe, MD, PhD, Pagnoux, Christian, MD, Bienvenu, Boris, MD, PhD
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Cyclophosphamide
Cyclophosphamide - therapeutic use
Dose-Response Relationship, Drug
Drug Therapy, Combination
Female
Giant Cell Arteritis - drug therapy
Giant-cell arteritis
Glucocorticoid dependence
Glucocorticoid iatrogeny
Glucocorticoids - therapeutic use
Humans
Immunosuppressive Agents - therapeutic use
Male
Middle Aged
Prednisone - therapeutic use
Rheumatology
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Objective To report on the effectiveness of cyclophosphamide (CYC) to treat glucocorticoid (GC)-dependent giant-cell arteritis (GCA) and/or severe GC-related side effects. Methods Fifteen patients with GCA and treated with CYC were retrieved from the computerized patient-record system. Glucocorticoid dependence was defined as a prednisone dose of >20 mg/day for 6 months or >10 mg/day for 1 year in order not to relapse. Response to CYC was defined as improved clinical and biological findings. Remission was defined as a sustained absence (>12 months) of active signs of vasculitis at a daily GC dose of
ISSN:0049-0172
1532-866X
DOI:10.1016/j.semarthrit.2012.12.023